CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.
CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.
复制标题
DOI：
--
复制
发表时间：
1996-07
期刊：
影响因子：
11.2
通讯作者：
M. Nagabhushan;C. Miller;T. P. Pretlow;Joseph M. Giaconia;N. Edgehouse;Stuart Schwartz;H. Kung;R. D. White;P. Gumerlock;M. Resnick;S. Amini;T. Pretlow
中科院分区：
文献类型：
--
作者：
M. Nagabhushan;C. Miller;T. P. Pretlow;Joseph M. Giaconia;N. Edgehouse;Stuart Schwartz;H. Kung;R. D. White;P. Gumerlock;M. Resnick;S. Amini;T. Pretlow
大多数患者的前列腺癌对雄激素剥夺有反应，但在几个月到几年的时间后复发。只有两种前列腺癌异种移植瘤，LNCaP和PC-346，据报道对雄激素剥夺有反应，并随后复发。这两种肿瘤都会轻微缩小，如果有的话，在雄激素停药后不到5周就会复发。停用雄激素后，人前列腺癌CWR22移植瘤显著消退，小鼠血液中的前列腺特异性抗原(PSA)下降了3000倍。PSA通常会恢复正常。在一些动物中，肿瘤复发，然后被命名为CWR22R。在这些动物中，PSA在大约2-7个月开始上升，肿瘤在去势后3-10个月开始生长。CWR22动物移植后6-12周，因肿瘤较大，需实施安乐死。停用雄激素可延长约3-4倍的寿命。
Most patients' prostate cancers respond to androgen deprivation but relapse after periods of several months to years. Only two prostate cancer xenografts, LNCaP and PC-346, have been reported to be responsive to androgen deprivation and to relapse subsequently. Both of these tumors shrink slightly, if at all, and relapse less than 5 weeks after androgen withdrawal. After androgen withdrawal, the human primary prostate cancer xenograft CWR22 regresses markedly, and prostate-specific antigen (PSA) falls up to 3000-fold in the blood of mice. PSA usually returns to normal. In some animals, the tumor relapses and is then designated CWR22R. In these animals, PSA starts to rise approximately 2-7 months, and tumor begins to grow 3-10 months after castration. Animals with CWR22 need to be euthanized because of large tumors 6-12 weeks after the transplantation of CWR22. Androgen withdrawal prolongs life approximately 3-4-fold.